Comparison of Bleeding Risk Scores in Atrial Fibrillation Patients on Direct-Acting Oral Anticoagulants: A Real-Life Study
Koşuyolu Heart Journal · 01.07.2026 · 29 (2) · 114-120
DOI: 10.51645/khj.2026.600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Koşuyolu Heart Journal, online erschienen am 08.06.2026. Verfasst von Yusuf İnci und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Objective
Hemorrhagic complications continue to be a major clinical challenge among individuals with atrial fibrillation (AF) receiving direct-acting oral anticoagulants (DOACs). This research sought to evaluate and contrast the accuracy of various risk assessment models in forecasting bleeding incidents within this specific patient cohort.
Methods
We enrolled 447 subjects diagnosed with AF who were prescribed DOAC therapy (including apixaban, dabigatran, edoxaban, or rivaroxaban). By retrospectively reviewing institutional electronic health records, we computed the ORBIT, ATRIA, and HEMORR 2 HAGES risk indices for each participant. The main outcome measures were defined as the occurrence of clinically relevant minor or major hemorrhages. Consequently, we analyzed how accurately these scoring systems could foresee the specified endpoints.
Results
The cohort’s average age stood at 75.6±10.1 years, comprising predominantly women (62.2%). During a 12-month observation period, 6.7% of the participants (n=30) encountered one or more major hemorrhagic events. When forecasting severe bleeding, the ATRIA, ORBIT, and HEMORR 2 HAGES frameworks exhibited comparable predictive accuracies without any statistically notable variations. Upon conducting a multivariate logistic regression, independent variables linked to a heightened likelihood of bleeding encompassed prior hemorrhagic episodes (odds ratio [OR]: 3.101, p=0.019) and the presence of heart failure (OR: 2.028, p=0.009). In addition, anemia emerged as a significant factor (OR: 0.366, p=0.049), alongside elevated evaluations in both the HEMORR 2 HAGES (OR: 1.535, p=0.006) and ORBIT (OR: 1.849, p
Zitieren
APA
İnci, Y., Barman, H. A., Okşen, D., Doğan, Ö., Ebeoğlu, A. Ö., Çayırlı, S., Sonsöz, M. R., Bilen, M. N., & Doğan, S. M. (2026). Comparison of Bleeding Risk Scores in Atrial Fibrillation Patients on Direct-Acting Oral Anticoagulants: A Real-Life Study. Koşuyolu Heart Journal, 29(2), 114-120. https://doi.org/10.51645/khj.2026.600
Vancouver
İnci Y, Barman HA, Okşen D, Doğan Ö, Ebeoğlu AÖ, Çayırlı S, et al. Comparison of Bleeding Risk Scores in Atrial Fibrillation Patients on Direct-Acting Oral Anticoagulants: A Real-Life Study. Koşuyolu Heart Journal. 2026;29(2):114-120. doi:10.51645/khj.2026.600
BibTeX
@article{nci2026,
author = {İnci, Yusuf and Barman, Hasan Ali and Okşen, Doğaç and Doğan, Ömer and Ebeoğlu, Abdullah Ömer and Çayırlı, Sercan and Sonsöz, Mehmet Rasih and Bilen, Mehmet Nail and Doğan, Sait Mesut},
title = {Comparison of Bleeding Risk Scores in Atrial Fibrillation Patients on Direct-Acting Oral Anticoagulants: A Real-Life Study},
journal = {Koşuyolu Heart Journal},
year = {2026},
volume = {29},
number = {2},
pages = {114--120},
doi = {10.51645/khj.2026.600}
}
EUVIMED